160 related articles for article (PubMed ID: 22064653)
1. Silencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cells.
Shih YP; Takada Y; Lo SH
Mol Cancer Res; 2012 Jan; 10(1):34-9. PubMed ID: 22064653
[TBL] [Abstract][Full Text] [Related]
2. Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance.
Ren F; Shi H; Zhang G; Zhang R
J Exp Clin Cancer Res; 2013 Aug; 32(1):60. PubMed ID: 23988121
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of DLC1 in endothelial cells compromises the angiogenesis process.
Shih YP; Yuan SY; Lo SH
Cancer Lett; 2017 Jul; 398():46-51. PubMed ID: 28408355
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation.
Cao X; Voss C; Zhao B; Kaneko T; Li SS
Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1455-60. PubMed ID: 22307599
[TBL] [Abstract][Full Text] [Related]
5. DLC1 negatively regulates angiogenesis in a paracrine fashion.
Shih YP; Liao YC; Lin Y; Lo SH
Cancer Res; 2010 Nov; 70(21):8270-5. PubMed ID: 20861185
[TBL] [Abstract][Full Text] [Related]
6. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).
Li G; Du X; Vass WC; Papageorge AG; Lowy DR; Qian X
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17129-34. PubMed ID: 21969587
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A.
Ravi A; Kaushik S; Ravichandran A; Pan CQ; Low BC
J Biol Chem; 2015 Feb; 290(7):4149-62. PubMed ID: 25525271
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of deleted in liver cancer 1 gene on gallbladder cancer growth through induction of cell cycle arrest and apoptosis.
Qin Y; Chu B; Gong W; Wang J; Tang Z; Shen J; Quan Z
J Gastroenterol Hepatol; 2014 May; 29(5):964-72. PubMed ID: 24329682
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration.
Heering J; Erlmann P; Olayioye MA
Exp Cell Res; 2009 Sep; 315(15):2505-14. PubMed ID: 19482022
[TBL] [Abstract][Full Text] [Related]
10. Promoter methylation of the DLC‑1 gene and its inhibitory effect on human colon cancer.
Dai Z; Jin Y
Oncol Rep; 2013 Sep; 30(3):1511-7. PubMed ID: 23783552
[TBL] [Abstract][Full Text] [Related]
11. Flavone inhibits migration through DLC1/RhoA pathway by decreasing ROS generation in breast cancer cells.
Zhu W; Ma L; Yang B; Zheng Z; Chai R; Liu T; Liu Z; Song T; Li F; Li G
In Vitro Cell Dev Biol Anim; 2016 May; 52(5):589-97. PubMed ID: 26935193
[TBL] [Abstract][Full Text] [Related]
12. Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1.
Tripathi BK; Grant T; Qian X; Zhou M; Mertins P; Wang D; Papageorge AG; Tarasov SG; Hunter KW; Carr SA; Lowy DR
J Cell Biol; 2017 Dec; 216(12):4255-4270. PubMed ID: 29114068
[TBL] [Abstract][Full Text] [Related]
13. Effects of DLC1 Deficiency on Endothelial Cell Contact Growth Inhibition and Angiosarcoma Progression.
Sánchez-Martín D; Otsuka A; Kabashima K; Ha T; Wang D; Qian X; Lowy DR; Tosato G
J Natl Cancer Inst; 2018 Apr; 110(4):390-399. PubMed ID: 29202196
[TBL] [Abstract][Full Text] [Related]
14. Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.
Chan LK; Ko FC; Ng IO; Yam JW
PLoS One; 2009; 4(5):e5572. PubMed ID: 19440389
[TBL] [Abstract][Full Text] [Related]
15. Functional relevance of D,L-sulforaphane-mediated induction of vimentin and plasminogen activator inhibitor-1 in human prostate cancer cells.
Vyas AR; Singh SV
Eur J Nutr; 2014 Apr; 53(3):843-52. PubMed ID: 24092501
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities.
Qian X; Li G; Asmussen HK; Asnaghi L; Vass WC; Braverman R; Yamada KM; Popescu NC; Papageorge AG; Lowy DR
Proc Natl Acad Sci U S A; 2007 May; 104(21):9012-7. PubMed ID: 17517630
[TBL] [Abstract][Full Text] [Related]
17. Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression.
Zhou X; Jiao D; Dou M; Zhang W; Lv L; Chen J; Li L; Wang L; Han X
J Cell Mol Med; 2020 Sep; 24(18):10648-10662. PubMed ID: 32725802
[TBL] [Abstract][Full Text] [Related]
18. Combination of dihydroartemisinin and resveratrol effectively inhibits cancer cell migration
Gao J; Ma F; Wang X; Li G
Food Funct; 2020 Nov; 11(11):9573-9584. PubMed ID: 33150340
[TBL] [Abstract][Full Text] [Related]
19. Tumor suppressor gene DLC1: Its modifications, interactive molecules, and potential prospects for clinical cancer application.
Ren G; Li G
Int J Biol Macromol; 2021 Jul; 182():264-275. PubMed ID: 33836193
[TBL] [Abstract][Full Text] [Related]
20. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
